Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double blind placebo-controlled study in children.

@article{Riikonen1994RecombinantHG,
  title={Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double blind placebo-controlled study in children.},
  author={Pekka Riikonen and Ulla M. Saarinen and Anne M-T M{\"a}kipernaa and Liisa Hovi and A Komulainen and Jaana Pihkala and Hannu J Jalanko},
  journal={The Pediatric infectious disease journal},
  year={1994},
  volume={13 3},
  pages={197-202}
}
In a double blind study of 58 episodes of fever and profound neutropenia, children with cancer received either recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) or placebo, combined with identical antimicrobial therapy, i.e. imipenem, on admission. The criteria for discontinuation of therapy were identical. A difference was demonstrated both in the number of hospital days, totaling 252 days in the rhGM-CSF group and 354 in the placebo group, days receiving… CONTINUE READING
20 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

Similar Papers

Loading similar papers…